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LossAbstract Introduction: Development of sensorineural hearing loss [SNHL] leads to severe hand-
icap that affects patient’s job, home and life. Therefore, otologists should diagnose potentially treat-
able disorders to improve and/or even stabilize hearing.
Aim of work: Evaluation of intra-tympanic corticosteroids for the treatment of different types of
SNHL.
Subjects and methods: Intra-tympanic injection of steroid under local anesthesia of 51 patients
suffering from immune-mediated SNHL. Audiological evaluation was done pre & post-injection.
Results: Hearing improvement of 23.41 dB by pure tone audiometry occurred in 43.2% of
patients. Speech discrimination scores had improved by 30.1% in 78.4% of patients.
Conclusion: Intra-tympanic steroid injection is a safe and promising tool for the treatment of
immune-mediated SNHL.
 2015 Egyptian Society of Ear, Nose, Throat and Allied Sciences. Production and hosting by Elsevier B.V.
All rights reserved.1. Introduction
Rapidly progressive deafness is a frightening condition as most
affected individuals have normal hearing prior to the onset of
hearing instability. It should be considered as an medical emer-gency for which deﬁnitive diagnosis and treatment are still lar-
gely vague. The single most important aspect of this disease,
from a physician standpoint, is the recognition that deafness
is potentially treatable, Harris et al.4
Recent clinical and laboratory evidence increasingly indi-
cates that most of the acquired SNHL are immune-mediated
diseases. These include:
 Idiopathic sudden sensorineural hearing loss (ISSNHL)
 Idiopathic progressive bilateral sensorineural hearing loss
(IPBSNHL)
 Meniere’s disease.ed.
Table 1 PTA results before & after treatment.
Group Number Before After P-value
ISSNHL 3 43.33 dB 66.66 dB 0.005
Meniere’s 7 64.00 dB 82.54 dB 0.001
IPBSNHL 12 53.33 dB 79.16 dB 0.001
Total 22 58.09 dB 78.41 dB 0.001
Table 2 SDS results before & after treatment.
Group Number Before (%) After (%) P-value
ISSNHL 4 32.00 65.25 0.001
Meniere’s 14 55.57 88.14 0.001
IPBSNHL 22 48.09 75.27 0.001
Total 40 49.10 79.02 0.001
Table 3 SDS & PTA correlation results.
Group Correlation coeﬃcient P value
ISSNHL 0.008 >0.05
Meniere’s 0.513* <0.05
IPBSNHL 0.402* <0.05
Total 0.356* <0.05
* Signiﬁcant correlation.
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treatment of SNHL hearing loss especially the immune medi-
ated group, McCabe.8
The systemic use is usually associated with systemic compli-
cations especially in high doses e.g. diabetes, GIT bleeding,
osteoporosis, hypertension or avascular necrosis of the head
of the femur especially if patients are predisposed or have a
milder form of the disease, Shea.13
Inner ear glucocorticoid receptors have been identiﬁed in
different animal models; Pitovski et al.11 Rarey and Curtis12
had substantiated this ﬁnding in human cadaveric temporal
bones. They identiﬁed receptors in both the cochlear and
vestibular tissues; with the highest concentration found in
the spiral ligament.
There is good experimental evidence that dexamethasone
readily passes through the round window membrane and that
it can be found in the lower and upper turns of the cochlea as
well as the vestibule in large quantities after being left against
the round window membrane for 3 h; Nomura.9 Parnes et al.10
found that intra-tympanic administration of steroids resulted
in signiﬁcantly higher inner ear concentration compared with
systemic administration.
2. Aim of work
Evaluation of intra-tympanic corticosteroids for the treatment
of Primary immune-mediated SNHL, as intra-tympanic appli-
cation of drugs is an attractive and possibly efﬁcacious method
of treatment that avoids systemic toxicities.
3. Subjects and methods
Fifty-one patients suffering from ISSNHL, IPBSNHL or
Meniere’s diseases were enrolled in our study done at Ain
Shams University, Cairo, Egypt. Their mean age was
43.56 years and their male: female ratio was 20:31 (children
were not included in the study). These were divided into three
groups; Twenty-seven patients were suffering from IPBSNHL,
18 were suffering from Meniere’s disease and 6 patients were
suffering from ISSNHL.
Their diagnosis was conﬁrmed through:
 Clinical picture: to exclude other ENT problems and to
select the patient groups enrolled.
 Basic audiological evaluation: including pure tone audiom-
etry (PTA) & speech discrimination score (SDS) tests to
determine baseline patients’ values before the start of
treatment.
 Advanced evaluation of selected patients from previous
basic evaluation to be submitted to Electrocochleography
(ECochG), to conﬁrm Meniere’s disease, &/or MRI to
exclude retro-cochlear lesions. Tympanometry, oto-
acoustic emissions (OAE) & auditory brain stem response
(ABR) tests were done on tests for auto-immune ear
diseases.
Pre-treatment counseling for possible beneﬁts and side
effects of the procedure was performed for all patients.
Intra-tympanic 12 mg dexamethasone (0.5 ml of 24 mg/ml)
was injected, so as to diffuse through the round window niche
to the inner ear, after local anesthesia by glycerin phenol 20%.The ear remains up for 30 min. A small opening in the anterior
part of the drum was made to allow air to escape while inject-
ing the drug. The procedure was repeated every third day for
three times.
Post-treatment audiological evaluation using PTA & SDS
were done in all patients after one week after the completion
of the three injections.
All data were tabulated and statistically analyzed using
SPSS software for windows. Mean values of different parame-
ters were compared using analysis of variance (ANOVA) or
Student t-test (paired and unpaired). P-values <0.05 were
considered signiﬁcant. Pearson and Spearman’s correlation
co-efﬁcient were also used.
4. Results
Intra-tympanic corticosteroid therapy for the treatment of
SNHL was done for 51 patients; with no signiﬁcant difference
in the age or sex between the three groups.
PTA results after intra-tympanic dexamethasone showed
improvement in 22 patients (43.13%) while SDS results
showed improvement in 40 patients (78.4%).
Improved PTA & SDS results obtained for each patient
group and for the total average threshold for the whole
patients after intra-tympanic injection were compared and sta-
tistically analyzed. It revealed a highly signiﬁcant improvement
(P-value <0.001); as shown in Tables 1 and 2 respectively.
The correlation between SDS and PTA results in the three
patient groups as a whole and in both IPBSNHL & Meniere’s
disease groups proved to be signiﬁcant. The ISSNHL group
results showed a non-signiﬁcant correlation; as shown in
Table 3.
Table 4 PTA & SDS correlation coefﬁcient with disease
duration.
Correlation coeﬃcient P value
PTA 0.063 >0.05
SDS 0.094 >0.05
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three patient groups with disease duration proved to be nega-
tive, but with statistically non-signiﬁcant correlation; as shown
in Table 4.5. Discussion
Intra-tympanic steroid injection is an easy and effective outpa-
tient procedure for the treatment of Meniere’s disease,
ISSNHL and IPBSNHL to avoid the side effects of systemic
corticosteroids.
Our study is in agreement with the protocol of Hamid.3 In
his four years experience with IT steroid injection, utilizing the
same technique we adopted in our study, he reported 90%
SDS recovery.
Li et al.6 demonstrated that intra-tympanic dexamethasone
perfusion by an external electronic pump with gelatin sponge
placement in a round window niche is an efﬁcacious and safe
method for the treatment of ISSNHL, showing superiority to
simple injection through the drum. This is in contrast to the
results we obtained utilizing the injection method that showed
a signiﬁcant improvement in our results that is nearly similar
to the better results obtained by their pump technique.
Garavello et al.2 concluded that Intra-tympanic steroid
therapy seems to confer a certain degree of beneﬁt as salvage
but not as a primary treatment of sudden deafness. This
contradicts our results that proved IT steroid therapy as an
effective primary therapy probably because of inclusion crite-
ria utilized in their meta-analysis study.
The mean PTA demonstrated a signiﬁcant therapeutic
action of the short-duration intra-tympanic steroid therapy
on moderate ISSNHL, with a ﬂat audiogram shape, compared
to the natural course of the disease and the placebo effect at
that time point; Filipo et al.1
Intra-tympanic treatment of ISSHL may be a preferable
choice as primary treatment option, since it can be performed
in outpatient settings, with no serious side effects and compli-
cation rate; Ljiljana et al.7
Ilker et al.5 reported that intra-tympanic steroid injections
could be used safely and successfully in patients who do not
respond to conventional intravenous treatment. It can also
be applied as the treatment of choice in ISHL, especially in
patients who have contraindications to systemic treatment
with corticosteroids. This, in concordance with our study,demonstrates the efﬁcacy of intra-tympanic steroid therapy
in cases of ISSHL.
6. Conclusion
The advantages of IT steroid therapy are being an ofﬁce based
procedure performed under local anesthesia, it is less invasive,
cost-effective, with no/minimal side effects and could be
started immediately, make it a superior tool in the treatment
of immune-mediated SNHL.
Statistically signiﬁcant results shown in our study, proves
its efﬁcacy and safety over the use of systemic steroids.
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